CLAIMS:

~~1. A composition comprising an effective amount of:~~

~~(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A as defined in Figures 78 A-E or a pharmaceutically acceptable salt thereof;~~

~~(b) about 0.5 mg/mL to about 20 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof; and one or both of:~~

~~(c) a buffer comprising about 1 mM to about 20 mM L-histidine capable of achieving or maintaining the pH of the composition at about pH 6.0;~~

~~(d) a tonicity modifier comprising about 10mM to about 200mM sodium chloride; and~~

~~(e) about 0.001% (w/v) to about 0.05% (w/v) surfactant.~~

~~2~~1. A composition comprising an effective amount of~~The composition of claim 1, wherein the composition comprises~~:

(a) about 3 mg/mL Antagonist A as defined in Figures 78 A-E or a pharmaceutically acceptable salt thereof;

(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof; and one or both of:

(c) a buffer comprising about 10 mM L-histidine capable of achieving or maintaining the pH of the composition at about pH 6.0;

(d) a tonicity modifier comprising about 130 mM NaCl; and

(e) about 0.01% (w/v) polysorbate 20 as surfactant,

wherein the pH of the composition is about pH 6.0.

~~3. A composition comprising an effective amount of:~~

~~(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A as defined in Figures 78 A-E or a pharmaceutically acceptable salt thereof; and~~

~~(b) about 0.5 mg/mL to about 25 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof; and one or both of:~~

~~(c) a buffer comprising about 5 mM to about 200 mM sodium phosphate capable of achieving or maintaining the pH of the composition at about pH 6.0;~~

~~(d) a tonicity modifier comprising about 10 mM to about 200 mM NaCl; and~~

~~(e) about 0.001% (w/v) to about 0.05% (w/v) surfactant.~~

42. A composition comprising an effective amount of~~The composition of claim 3, wherein the composition comprises~~:

(a) about 3 mg/mL Antagonist A as defined in Figures 78 A-E or a pharmaceutically acceptable salt thereof;

(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof; and one or both of:

(c) about 50 mM sodium phosphate capable of achieving or maintaining the pH of the composition at about pH 6.0; and

(d) a tonicity modifier comprising about 130 mM NaCl;

(e) about 0.02% (w/v) polysorbate 20 as surfactant,

wherein the pH of the composition is about pH 6.0.

53. The composition of ~~any one of~~ claims 1 ~~to 4~~or 2 for use in a method for treating or preventing an ophthalmological disease in a mammal.

64. The composition for the use of claim 53, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

75. The composition for the use of claim 53, wherein the ophthalmological disease is wet age-related macular degeneration or dry age-related macular degeneration.

~~8~~6. The composition for the use of claim ~~5~~3, wherein the composition is present in a drug-delivery device.

~~9~~7. The composition for the use of any one of claims ~~5–8~~3-6, wherein the composition is for intraocular administration.

~~10~~8. The composition for the use of claim ~~9~~7, wherein the intraocular administration is intravitreal administration or anterior chamber administration.

~~11~~9. The composition for the use of any one of claims ~~5–10~~3-8, wherein the mammal is a human.

~~12~~10. Use of the composition according to ~~any one of~~ claims 1 or 2~~to~~4 for the preparation of a medicament for treating or preventing an ophthalmological disease in a mammal.

~~13~~11. Use of claim ~~12~~10, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

~~14~~12. Use of claim ~~12~~10, wherein the ophthalmological disease is wet age-related macular degeneration or dry age-related macular degeneration.

~~15~~13. Use of any one of claims ~~12~~-10 to ~~14~~12, wherein the medicament is for intraocular administration.

~~16~~14. Use according to claim ~~15~~13, wherein the intraocular administration is intravitreal administration or anterior chamber administration.

~~17~~15. Use according to any one of claims ~~12~~ 10 to ~~16~~14, wherein the mammal is a human.